189 related articles for article (PubMed ID: 26975374)
21. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.
Lin DP; Wang Y; Scherer SJ; Clark AB; Yang K; Avdievich E; Jin B; Werling U; Parris T; Kurihara N; Umar A; Kucherlapati R; Lipkin M; Kunkel TA; Edelmann W
Cancer Res; 2004 Jan; 64(2):517-22. PubMed ID: 14744764
[TBL] [Abstract][Full Text] [Related]
22. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2.
Adamson AW; Beardsley DI; Kim WJ; Gao Y; Baskaran R; Brown KD
Mol Biol Cell; 2005 Mar; 16(3):1513-26. PubMed ID: 15647386
[TBL] [Abstract][Full Text] [Related]
23. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.
Russo MT; De Luca G; Casorelli I; Degan P; Molatore S; Barone F; Mazzei F; Pannellini T; Musiani P; Bignami M
Cancer Res; 2009 May; 69(10):4372-9. PubMed ID: 19435918
[TBL] [Abstract][Full Text] [Related]
24. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
25. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
26. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6.
Umar A; Koi M; Risinger JI; Glaab WE; Tindall KR; Kolodner RD; Boland CR; Barrett JC; Kunkel TA
Cancer Res; 1997 Sep; 57(18):3949-55. PubMed ID: 9307278
[TBL] [Abstract][Full Text] [Related]
27. Compromised repair of clustered DNA damage in the human acute lymphoblastic leukemia MSH2-deficient NALM-6 cells.
Holt SM; Scemama JL; Panayiotidis MI; Georgakilas AG
Mutat Res; 2009 Mar; 674(1-2):123-30. PubMed ID: 18955159
[TBL] [Abstract][Full Text] [Related]
28. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents.
Dosch J; Christmann M; Kaina B
Carcinogenesis; 1998 Apr; 19(4):567-73. PubMed ID: 9600339
[TBL] [Abstract][Full Text] [Related]
29. The expression of MLH1 and MSH2 genes among inhabitants of high background radiation area of Ramsar, Iran.
Bakhtiari E; Monfared AS; Niaki HA; Borzoueisileh S; Niksirat F; Fattahi S; Monfared MK; Gorji KE
J Environ Radioact; 2019 Nov; 208-209():106012. PubMed ID: 31323602
[TBL] [Abstract][Full Text] [Related]
30. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
31. TRAF Family Member-associated NF-κB Activator (TANK) Inhibits Genotoxic Nuclear Factor κB Activation by Facilitating Deubiquitinase USP10-dependent Deubiquitination of TRAF6 Ligase.
Wang W; Huang X; Xin HB; Fu M; Xue A; Wu ZH
J Biol Chem; 2015 May; 290(21):13372-85. PubMed ID: 25861989
[TBL] [Abstract][Full Text] [Related]
32. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase.
Franchitto A; Pichierri P; Piergentili R; Crescenzi M; Bignami M; Palitti F
Oncogene; 2003 Apr; 22(14):2110-20. PubMed ID: 12687013
[TBL] [Abstract][Full Text] [Related]
33. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
[TBL] [Abstract][Full Text] [Related]
34. Msh2 deficiency increases susceptibility to benzo[a]pyrene-induced lymphomagenesis.
Zienolddiny S; Ryberg D; Svendsrud DH; Eilertsen E; Skaug V; Hewer A; Phillips DH; te Riele H; Haugen A
Int J Cancer; 2006 Jun; 118(11):2899-902. PubMed ID: 16381012
[TBL] [Abstract][Full Text] [Related]
35. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
36. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair protein Msh2 contributes to UVB-induced cell cycle arrest in epidermal and cultured mouse keratinocytes.
van Oosten M; Stout GJ; Backendorf C; Rebel H; de Wind N; Darroudi F; van Kranen HJ; de Gruijl FR; Mullenders LH
DNA Repair (Amst); 2005 Jan; 4(1):81-9. PubMed ID: 15533840
[TBL] [Abstract][Full Text] [Related]
38. HDAC6 regulates DNA damage response via deacetylating MLH1.
Zhang M; Hu C; Moses N; Haakenson J; Xiang S; Quan D; Fang B; Yang Z; Bai W; Bepler G; Li GM; Zhang XM
J Biol Chem; 2019 Apr; 294(15):5813-5826. PubMed ID: 30770470
[TBL] [Abstract][Full Text] [Related]
39. Roles of MSH2 and MSH6 in cadmium-induced G2/M checkpoint arrest in Arabidopsis roots.
Cao X; Wang H; Zhuang D; Zhu H; Du Y; Cheng Z; Cui W; Rogers HJ; Zhang Q; Jia C; Yang Y; Tai P; Xie F; Liu W
Chemosphere; 2018 Jun; 201():586-594. PubMed ID: 29533809
[TBL] [Abstract][Full Text] [Related]
40. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level.
Claij N; Te Riele H
Oncogene; 2002 Apr; 21(18):2873-9. PubMed ID: 11973647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
